title: Preconditioning thermal therapy: flipping the switch on IL-6 for anti-tumour immunity.
abstract: Cancer immunotherapy aims to generate long-lived, tumour-specific adaptive immunity to limit dysregulated tumour progression and metastasis. Tumour vasculature has emerged as a critical checkpoint controlling the efficacy of immunotherapy since it is the main access point for cytotoxic T cells to reach tumour cell targets. Therapeutic success has been particularly challenging to achieve because of the local, cytokine-rich inflammatory milieu that drives a pro-tumourigenic programme supporting the growth and survival of malignant cells. Here, we focus on recent evidence that systemic thermal therapy can switch the activities of the inflammatory cytokine, interleukin-6 (IL-6), to a predominantly anti-tumourigenic function that promotes anti-tumour immunity by mobilising T cell trafficking in the recalcitrant tumour microenvironment.
authors.affiliation: Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
authors.forename: Maryann E
authors.initials: ME
authors.lastname: Mikucki
authors.forename: Daniel T
authors.initials: DT
authors.lastname: Fisher
authors.forename: Amy W
authors.initials: AW
authors.lastname: Ku
authors.forename: Michelle M
authors.initials: MM
authors.lastname: Appenheimer
authors.forename: Jason B
authors.initials: JB
authors.lastname: Muhitch
authors.forename: Sharon S
authors.initials: SS
authors.lastname: Evans
mesh_terms: D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D006801:Humans; D006979:Hyperthermia, Induced; D016219:Immunotherapy, Adoptive; D015850:Interleukin-6 / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D059016:Tumor Microenvironment / Q000276:immunology
chemical_list: D015850:Interleukin-6